236 related articles for article (PubMed ID: 29292710)
1. Importance of repeat tissue biopsy and tissue-based epidermal growth factor receptor T790M testing in progressed nonsmall cell lung carcinoma patients upon negative plasma genotyping for selection of third-generation tyrosine kinase inhibitor therapy: A case study.
Mistry R; Patil A
Indian J Cancer; 2017 Dec; 54(Supplement):S65-S66. PubMed ID: 29292710
[TBL] [Abstract][Full Text] [Related]
2. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
[TBL] [Abstract][Full Text] [Related]
3. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
4. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
5. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
[TBL] [Abstract][Full Text] [Related]
6. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
[TBL] [Abstract][Full Text] [Related]
7. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.
Aggarwal S; Patil S; Rohtagi N
Indian J Cancer; 2017 Dec; 54(Supplement):S15-S24. PubMed ID: 29292704
[TBL] [Abstract][Full Text] [Related]
9. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
10. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
[TBL] [Abstract][Full Text] [Related]
11. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
12. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EGFR T790M mutation in non-small-cell lung cancer.
Normanno N; Maiello MR; Chicchinelli N; Iannaccone A; Esposito C; De Cecio R; D'alessio A; De Luca A
Expert Opin Ther Targets; 2017 Feb; 21(2):159-165. PubMed ID: 28002980
[TBL] [Abstract][Full Text] [Related]
14. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
15. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.
Zhang S; Zhu L; Xia B; Chen E; Zhao Q; Zhang X; Chen X; Chen X; Ma S
Cancer Commun (Lond); 2018 May; 38(1):28. PubMed ID: 29789021
[TBL] [Abstract][Full Text] [Related]
17. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
[TBL] [Abstract][Full Text] [Related]
18. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
Kimura H; Nishikawa S; Koba H; Yoneda T; Sone T; Kasahara K
Adv Exp Med Biol; 2016; 924():171-174. PubMed ID: 27753039
[TBL] [Abstract][Full Text] [Related]
19. Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Sundaresan TK; Sequist LV; Heymach JV; Riely GJ; Jänne PA; Koch WH; Sullivan JP; Fox DB; Maher R; Muzikansky A; Webb A; Tran HT; Giri U; Fleisher M; Yu HA; Wei W; Johnson BE; Barber TA; Walsh JR; Engelman JA; Stott SL; Kapur R; Maheswaran S; Toner M; Haber DA
Clin Cancer Res; 2016 Mar; 22(5):1103-10. PubMed ID: 26446944
[TBL] [Abstract][Full Text] [Related]
20. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
